FindTrial
Sign In

Clinical study of SM-11355 in patients with hepatocellular carcinoma (Phase III Study)

Clinical study of SM-11355 in patients with hepatocellular carcinoma (Phase III Study)

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220609
Enrollment
Unknown
Registered
2008-09-18
Start date
2008-09-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

investigational material(s) Generic name etc : SM-11355 (Miriplatin Hydrate) INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Inv

Sponsors

Dainippon Sumitomo Pharma Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients histologically and/or clinically diagnosed with hepatocellular carcinoma, with a measurable lesion, patients with tumor stain in contrast enhanced CT imaging, patients for whom hepatectomy, PEIT, PMCT, or RFA is not indicated

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy: Overall survival—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026